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Abstract
Background: The clinical course of ulcerative colitis (UC) and the effects of treatment are assessed through patient-
reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Ulcerative Colitis Patient-
Reported Outcomes Signs and Symptoms (UC-PRO/SS) measure was developed to standardize the quantification of
gastrointestinal S&S of UC in clinical trials through direct report from patient ratings.
Design: The UC-PRO/SS was developed by collecting data from concept elicitation (focus groups, and individual
interviews), then refined through a process of cognitive interviews of 57 UC patients. Measurement properties,
including item-level statistics, scaling structure, reliability, and validity, were evaluated in an observational, four-week
study of adults with mild to severe UC (N = 200).
Results: Findings from qualitative focus groups and interviews identified nine symptom items covering bowel and
abdominal symptoms. The final UC-PRO/SS daily diary includes two scales: Bowel S&S (six items) and Abdominal
Symptoms (three items), each scored separately. Each scale showed evidence of adequate reliability (α = 80 and 0.
66, respectively); reproducibility (intraclass correlation coefficient = 0.81, 0.71) and validity, including moderate-to-
high correlations with the Partial Mayo Score (0.79; 0.45) and Inflammatory Bowel Disease Questionnaire (IBDQ) total
score (− 0.70; − 0.61). Scores discriminated by level of disease severity, as defined by the Partial Mayo Score, Patient
Global Rating, and Clinician Global Rating (p < 0.0001).
Conclusions: Results suggest that the UC-PRO/SS is a reliable and valid measure of gastrointestinal symptom
severity in UC patients. Additional longitudinal data are needed to evaluate the ability of the UC-PRO/SS scores to
detect responsiveness and inform the selection of responder definitions.
Keywords: Ulcerative colitis, Patient-reported outcomes, Signs and symptoms, Reliability, Validity, Clinical trial
endpoints
Significance of this study
What is already known about this subject?
 The US Food and Drug Administration (FDA) has
established a pathway for rigorous development of
disease-specific Patient-reported Outcome (PRO)
tools for clinical trials and clinical use.
 Currently, there are no measures developed and
validated according to the FDA PRO guidance
available to assess the symptoms of ulcerative colitis
(UC).
What are the new findings?
 Using the US FDA pathway for rigorous
development of disease-specific PRO tools, we have
developed and validated a new patient-reported sign* Correspondence: phiggins@umich.edu
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and symptoms measure for clinical trials and clinical
use in UC.
 This is the first symptom measure of UC to meet
US FDA PRO guidelines.
 This modular instrument can be used with
appropriate individual modules customized to the
mechanism of action of a candidate therapy, from
purely anti-inflammatory medications, to those tar-
geting pain, dysmotility, or functional symptoms.
How might it impact on clinical practice in the fore-
seeable future?
 Using electronic device systems, PROs in IBD can
be routinely measured before and between
appointments in order to identify response to
therapies or failure of therapies.
Background
Ulcerative colitis (UC) is a chronic, relapsing inflamma-
tory disease of the colonic mucosa [1]. Recent studies es-
timate that 700,000 people are afflicted in the United
States (US) and Canada alone [2], with a global annual
incidence ranging from 0.5 to 24.5 cases per 100,000 [3].
The characteristic signs and symptoms of UC include
abdominal pain, frequent diarrhea, urgent bowel move-
ments, and rectal bleeding, which are not only discon-
certing to patients, but can adversely affect their quality
of life [4].
Clinically, UC is monitored through signs and symp-
toms of disease activity and periodic objective assess-
ment (e.g., an endoscopy) to evaluate mucosal
inflammation. In clinical trial settings, the Mayo Score
historically has been used to assess disease activity, com-
bining endoscopic findings with physician-rated signs
and symptoms, based on information provided by the
patient in a single total score.
In 2009, the US Food and Drug Administration (FDA)
released a guidance for the development of patient-
reported outcome (PRO) measures to support labeling
claims for new medical treatments and products [5].
This guidance emphasizes the importance of conducting
qualitative research throughout the process of instru-
ment development to ensure that the content of the
measure is consistent with the patient experience and
covers what they consider most important about a con-
dition and/or treatment intervention. Quantitative work
to assess the instrument’s psychometric properties, such
as reliability and validity, is also recommended. This
standard in instrument development is an increasing
regulatory requirement for efficacy evaluation and label-
ing purposes for treatment interventions [5, 6]. Compos-
ite measures that combine different aspects of a disease,
such as clinically derived signs, patient symptoms, and/
or clinical tests, are now viewed by the FDA as concepts
that are best measured, scored, and reported separately.
Furthermore, both the FDA and European Medicines
Agency have recently released guidelines specific to clin-
ical trials of ulcerative colitis, noting the importance of
including an adequately validated PRO to assess symp-
tomatic relief as a primary outcome measure in pivotal
clinical trials of UC [7, 8]. For these reasons, a new
patient-reported sign and symptom measure for UC was
developed and validated according to the US FDA PRO
Guidance and is the first symptom measure of UC to
meet these guidelines.
The Ulcerative Colitis Patient-reported Outcomes
(UC-PRO) instrument was designed to comprehensively
assess the signs, symptoms, and impact of UC through
six modules. Modules 1 (Bowel Signs and Symptoms)
and 2 (Abdominal Symptoms) comprise the UC-PRO
Signs and Symptoms (UC-PRO/SS) measure. Module 3
addresses Systemic Symptoms, Module 4 addresses Cop-
ing Strategies, Module 5 addresses Daily Life Impact,
and Module 6 covers Emotional Impact. Any or all of
these modules may be used in any given study.
The focus of this paper is on evaluating the UC-PRO/
SS measure in terms of treatment-related outcomes and
supporting potential labeling claims related to the
gastrointestinal (GI) signs of symptoms of UC from the
perspective of the patient. The UC-PRO/SS was devel-
oped to quantify the signs and symptoms in clinical tri-
als of adults (18 years of age or older) with moderate-to-
severe UC treated in outpatient settings. This paper de-
scribes the development and initial validation of this in-
strument. Given the variability in the symptomatic
experience of this patient population, the UC-PRO/SS is
completed as a daily diary, and is designed for electronic
administration.
As noted throughout the paper, details related to the
UC-PRO/SS development and validation are provided in
the online Supplementary Material. Also included in the
Supplementary Material is information on the Systemic
Symptoms scale (Module 3 of the UC-PRO), a five item
scale that can be included as part of the daily diary to
evaluate the non-gastrointestinal systemic symptoms of
UC. Based on the qualitative work, these symptoms were
found to be relevant and important to the patient ex-
perience. However, systemic symptoms are generally not
affected by current gut-specific agents. From a regula-
tory perspective, such symptoms are considered “distal”
to the target disease activity and are therefore less suit-
able for testing treatment effects and/or inclusion in a
product label. Because the intent is to use the UC-PRO/
SS in drug development trials, with the qualification of
the instrument as a Drug Development Tool for this
purpose currently underway [9], Module 3, Systemic
Symptoms, is not included in the CD-PRO/SS measures.
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At the discretion of the user/sponsor, it can be adminis-
tered as part of a diary and serve as an exploratory as-
sessment in clinical trials. This scale may also be useful
in studies or clinical trials evaluating the systemic com-
ponent of UC. Information in the online Supplementary
Material is intended to facilitate use of this Module.
Methods
The research was conducted in two phases, consistent
with the methodology outlined by the FDA PRO Guid-
ance [5]. Phase I addressed the content and structure of
the measure, and the documentation of content validity
through qualitative research methods. Phase II was a
four-week observational study to address its measure-
ment properties, including scoring and evaluation of re-
liability and validity. All data collection and recruitment
procedures met institutional review board (IRB) and
Health Insurance Portability and Accountability Act re-
quirements, and all applicable state and federal laws and
regulations. Study protocols were approved by an inde-
pendent IRB and written informed consent was obtained
from study subjects prior to completing any study re-
lated activities.
For each phase, subjects were recruited from US
gastroenterology clinics and included ambulatory adult
patients with clinician-confirmed UC, based on available
biopsy. Patients participating in an interventional study
were excluded, as were those with an ileostomy, colos-
tomy, or who had an intra-abdominal surgery in the 4
months prior to screening. Patients represented a range
of disease activity, from mild to severe, based on the
Simple Clinical Colitis Activity Index (SCCAI) or Partial
Mayo score [10].
Phase I: Qualitative – Development and content validity
A two-stage qualitative research process was used to de-
termine instrument content, and to ensure clarity and
understanding in the target patient population. Focus
groups and interviews were conducted by experienced
study team members using a semi-structured discussion
guide, informed by clinical expert input and a review of
the literature to cross reference symptoms, and were
audio-recorded and transcribed for analysis. Addition-
ally, participants completed a sociodemographic ques-
tionnaire for use in characterizing the study sample.
Additional methods are outlined below, with details pro-
vided in the online Supplementary Material.
Stage 1: Focus groups and one-to-one interviews
Six focus groups (n = 33) and one-to-one qualitative in-
terviews (n = 9) were conducted to identify important
UC symptoms, explore the frequency and variability of
these symptoms, and inform the development of re-
sponse options and appropriate recall for a symptom
measure in the target population. Subjects were re-
cruited from seven US gastroenterology sites to capture
diversity in terms of race, ethnicity, and geographic loca-
tion. In addition, subjects represented a range of disease
activity, based on the SCCAI for focus group partici-
pants (SCCAI ≤5, n = 3; SCCAI 6–8, n = 5; and SCCAI
≥8, n = 23 [SCCAI data were missing for two partici-
pants]) and the Partial Mayo Scores for those participat-
ing in one-to-one interviews (Partial Mayo Score 2–4, n
= 5; Partial Mayo Score ≥ 4, n = 4). Discussion focused
on participants’ current symptom experiences, their ex-
periences during an episode or flare-up, and the impact
of these symptoms on their daily life.
Content analyses were performed by independent
coders, with data organized using qualitative software
(NVivo or ATLAS.ti). At each stage of instrument devel-
opment, participant quotes were grouped and summa-
rized by thematic code to assess the saturation of
concepts. Saturation is defined as the point at which no
substantially new themes, descriptions of a concept, or
terms are introduced as additional discussions are con-
ducted [11].
Results were discussed with clinical experts and used
to generate a list of relevant symptoms and a draft UC-
PRO/SS measure, including instructions, items, and re-
sponse options.
Stage 2: Cognitive interviews
Two rounds of cognitive interviews (n = 15) were con-
ducted at three US clinical sites to examine the rele-
vance, comprehensiveness, and clarity of the draft UC-
PRO/SS (including systemic symptoms), and to refine
the measure as needed. Subjects were asked to complete
the questionnaire independently and were then inter-
viewed about the content, including instructions, recall
period, candidate items, and response options. Upon
completion of 10 interviews (Round 1), the instrument
was edited for clarity based on subject comments, and
the revised instrument was evaluated by a new sample of
UC patients (Round 2, n = 5). Round 2 also provided an
opportunity to examine patient understanding of the
scales formatted as ePRO screen shots for use as an elec-
tronic daily diary, with one item per page. Upon comple-
tion of this set of interviews, the instrument was
finalized for psychometric evaluation.
Phase II: Quantitative – Reliability and validity
An observational, prospective, four-week study was con-
ducted to examine the reliability and validity of the UC-
PRO/SS in ambulatory adults with clinician-confirmed
UC based on a biopsy obtained at least 3 months prior
to study screening. Participants represented a range of
disease severity based on the Partial Mayo Score (0–2, n
= 56 [28%]; 3–5, n = 88 [44%]; ≥6, n = 56 [28%]). Subjects
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were recruited for the psychometric study (Phase II)
from 22 study sites in diverse regions of the US. Each
participated in three protocol-driven clinic visits: Day 1
(Enrollment: Visit 1), Day 7 ± 3 days (Visit 2), and Day
28 ± 4 days (Visit 3).
Measures
Subjects completed the UC-PRO/SS (9 candidate items)
and Module 3 Systemic Symptoms (5 candidate items), a
patient global rating of disease severity, and a single item
to assess the “worst pain” [12] each day during the 30-
day study period, using an electronic hand-held device
given to the subject upon enrollment; training was pro-
vided by clinical site personnel. In addition, subjects
completed the paper-pen Partial Mayo Symptom Diary 7
days prior to Visits 2 and 3.
For score validation purposes, and to coincide with the
clinician assessment, the following paper-pen question-
naires were completed by subjects at Visits 2 and 3,
prior to seeing the clinician: Inflammatory Bowel Dis-
ease Questionnaire – 32 Items (IBDQ-32) [13, 14], Work
Productivity and Activity Impairment – Specific Health
Problem (WPAI-SHP) [15], Patient-Reported Outcomes
Measurement Information System (PROMIS) Global
Health Scale [16], a patient global rating of disease se-
verity, and a patient global rate of change in disease
severity.
Clinicians completed the Partial Mayo Score at Visits
2 and 3 based on their assessment of patients’ answers
to the paper-pen Partial Mayo Symptom Diary and a
clinical assessment after seeing the patient. This measure
is highly correlated (0.71) with the full Mayo score [10],
which includes flexible sigmoidoscopy. In addition, clini-
cians completed a clinician global rating of disease sever-
ity at each clinic visit, and a clinician global rating of
changes in disease severity at clinic Visits 2 and 3.
Statistical analysis
Analyses were performed in accordance with a pre-
specified statistical analysis plan. SAS version 9.2 was
used for all statistical analyses, excepting the confirma-
tory factor analysis (conducted with Mplus) [17], and the
Rasch analysis (conducted with RUMM2030) [18]. Item-
level analyses were evaluated using the “worst” day be-
tween (and inclusive of ) Visit 1 and Visit 2, defined as
the day with the worst rating on the patient global rating
of disease severity. These analyses included measures of
central tendency, floor and ceiling effects, and inter-item
correlations. An item was flagged for potential problems
if it showed a floor (minimum response > 25%) or ceiling
effect (maximum response > 25%), or when the inter-
item correlation was greater than 0.80. Confirmatory
and exploratory factor analyses were performed to evalu-
ate the structure of the measure and develop a scoring
algorithm. Rasch analyses were conducted separately for
each factor that consisted of a single dimension; items
with negative fit residual value ≤ − 3.0 or ≥ 3.0 positive fit
residual were flagged for potential deletion [19].
After the items and scales were finalized, scores were
evaluated for reliability and validity. Specifically, internal
consistency reliability was assessed using Cronbach’s
alpha coefficient, with a target value of 0.7 indicating
good internal consistency [20, 21]. Test-retest reliability
was assessed between Day 1 and Day 7 among those
with no change in patient-rated global rating of change
in UC severity at Visit 2. Intraclass correlation coeffi-
cients (ICC) were computed, where ≥0.7 indicates ad-
equate reproducibility [21, 22].
Score validity was assessed by examining correlations
of the UC-PRO/SS with the Partial Mayo Score; IBDQ;
WPAI-SHP; PROMIS measures of global physical health
(GPH), global mental health (GMH), general health, and
satisfaction with social role scores; worst pain; and pa-
tient and clinician global ratings of disease severity. The
UC-PRO/SS was expected to be moderately-to-highly
correlated (> 0.30) with Partial Mayo Scores and moder-
ately correlated (0.30–0.50) with IBDQ scores, worst
pain, PROMIS GPH, and patient-rated global ratings of
disease severity, demonstrating convergent validity [23].
Lower correlations were anticipated between the UC-
PRO/SS scales and PROMIS GMH and satisfaction
scores, and WPAI-SHP scores (overall work impairment
and activity impairment) (≤0.30), as these concepts were
thought to be more distal to the symptom experience.
Known-groups validity was examined to determine
whether the UC-PRO/SS could distinguish between pa-
tients by disease severity, defined in three ways: 1) by
Partial Mayo Scores (mild, score 0–4; moderate, score
5–7, severe, score ≥ 8); 2) by clinician-rated global as-
sessment of disease severity; and 3) by patient-rated dis-
ease severity. Analysis of covariance models with
baseline clinical measurement group as the main effects
in the model were used, adjusting for age and gender.
Results
Study samples
Demographics and clinical characteristics for the study
samples by phase are shown in Table 1. The study sub-
jects ranged in age from 21 to 80 years of age, represent-
ing a range of ethnicity, race, extent of disease, and
disease severity (at baseline).
Phase I: Development and content validity
Findings from focus groups and individual interviews
identified nine sign and symptom items covering bowel
and abdominal symptoms. Important bowel-related
symptoms from the perspective of the patient included
frequency of bowel movements (BMs), consistency of
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BMs, the presence of blood, the presence of mucus, the
urge/need to have a BM right away, and leakage/acci-
dents. Key abdominal symptoms included pain in stom-
ach area, bloating, and gas. The symptoms that were
most relevant during flare-ups included blood in BMs,
frequency of BMs, consistency of BMs, and urge/need to
have a BM right away. Patient descriptions of the symp-
toms they experienced during a flare were similar to lan-
guage they used to describe their everyday symptoms,
just more severe and/or persistent. Patient descriptions
of their symptom experience underline the variability
not only within, but also between patients.
Additional details of the qualitative methods and re-
sults, along with evidence of saturation, are provided in
the online Supplementary Material.
The final version, which was ready for quantitative
testing, was a daily diary that comprised nine candidate
symptom items covering all GI signs and symptoms
identified by patients and confirmed by clinicians as
relevant and important to the assessment of disease ac-
tivity in UC. For number and consistency of bowel
movements, response options were based on frequency.
The number of bowel movements was queried on a 8-
point scale with ranges considered reasonable and mean-
ingful to patients and clinicians (0, 1–2, 3–4, 5–6, 7–9,
10–12, 13–17, 18–24, more than 24). The intent was to
use quantitative data to evaluate these categories, with
the possibility of combining and/or deleting categories,
while maintaining a clinically meaningful and sensitive
indicator of bowel movement frequency. For all other
symptoms, response options were based on presence
(yes/no) and severity or frequency of each, with scores
ranging from 0 (none or not at all) to 4 (always or very
severe).
Phase II: Reliability and validity
Item and factor analysis and scoring algorithm Item-
by-item descriptive statistics are shown in Table 2. Sub-
jects used the full range of response options for each
item, with the exception of the item concerning number
of bowel movements; as anticipated, no study
Table 1 Patient Demographic and Clinical Characteristics, by Study Phase*
Characteristics Phase I: Qualitative Development and Content Validity
(n = 57)
Phase II: Quantitative Score Reliability and Validity
(n = 200)
Age in years, Mean (SD) [Range] 44.1 (13.8) [21–77] 45.7 (14.60) [21–80]
Gender, n (%)
Female 36 (63%) 117 (59%)
Ethnicity, n (%)
Hispanic or Latino 6 (10%) 42 (21%)
Not Hispanic or Latino 50 (88%) 155 (78%)
Missing 1 (2%) 3 (2%)
Race, n (%)†
American Indian or Alaska Native 1 (2%) 2 (10%)
Asian 1 (2%) 11 (6%)
Black or African American 3 (5%) 28 (14%)
Native Hawaiian or other Pacific
Islander
1 (2%) 2 (1%)
White 43 (75%) 153 (77%)
Other 6 (10%) 6 (3%)
Missing 2 (4%) 0 (0%)
Extent of Disease, n (%)a
Ulcerative proctitis 4 (7%) 19 (10%)
Proctosigmoiditis 9 (16%) 62 (31%)
Left-sided colitis 14 (25%) 59 (30%)
Extensive colitis 2 (4%) 18 (9%)
Pancolitis 25 (44%) 42 (21%)
Missing or unknown 3 (5%) 0 (0%)
Abbreviations: n number, SD standard deviation
aPercents do not add to 100 due to rounding
bSubjects able to choose more than one race
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participants reported zero BMs on their “worst” day be-
tween Visits 1 and 2. Six of nine items had a floor effect
exceeding 25%, with nearly half of these outpatients
reporting no leakage (62%), and no mucus (53%) or
blood (47%) in their stool between Visit 1 and Visit 2 on
their worst symptom day during this one-week observa-
tion period. There were no ceiling effects.
Findings support a two-factor solution, with confirma-
tory factor analyses subsequently conducted to deter-
mine goodness of fit statistics. One factor represents
“Bowel Signs and Symptoms” and includes six items
(Comparative Fit Index [CFI] = 0.98, Root Mean Square
of Approximation [RMSEA] = 0.068, Weighted Root
Mean Residual [WRMR] = 0.563), while the other factor
represents “Abdominal Symptoms” and includes three
items (CFI = 1.0, RMSEA = 0.0, WRMR = 0.0). Rasch
analysis indicated that all of the fit residuals for items in
each of the two models fell within the acceptable range
(≥ − 3.0 and ≤ 3.0); however, several of the response cat-
egories were not ordered correctly, primarily due to very
few responses for “rarely” and “mild” categories.
Taking into consideration findings from both the
qualitative and quantitative studies, several decisions
were reached regarding the UC-PRO/SS. First, given that
few subjects (n = 6, 3%) endorsed the response category
“more than 24” for the item “number of BMs,” this item
response level was removed. Although a number of
items demonstrated floor effects during the one-week
observation, all were considered important from the per-
spective of the patient, based on qualitative studies, and
clinically relevant. Finally, although the Rasch analyses
suggested the number of response options for several
items could be reduced from a 5- to a 4-point scale by
combining responses, the distinction between “none”
and “mild” and between “mild” and “moderate” was con-
sidered clinically important and the decision was made
to retain the five-point scaling.
The final UC-PRO/GI-SS assesses two important indi-
cators of disease activity in UC: Bowel Signs and
Symptoms (six items) and Abdominal Symptoms (three
items), each scored as a simple mean across all items
comprising the scale. There is no single total score that
combines both scales.
Reliability
Adequate internal consistency was demonstrated with
alpha coefficients of 0.80 for Bowel Signs and Symptoms
and 0.66 for Abdominal Symptoms. Although findings
indicate that the Cronbach’s alpha for the domain of Ab-
dominal Symptoms would increase to 0.79 with the dele-
tion of “passing gas,” the item was retained based on
importance of this symptom from the patient perspec-
tive and expert opinion. Seven-day test-retest reliability
in stable patients (n = 77 reporting no change in symp-
toms between Day 1 and Day 7) was supported with
ICC values of 0.81 and 0.71 for Bowel Signs and Symp-
toms and Abdominal Symptoms, respectively.
Validity
Correlations between the UC-PRO/SS domain scores
and clinical and other relevant PRO measures are pre-
sented in Table 3. All relationships were confirmed
based on a priori predictions, with both UC-PRO/SS
scale scores demonstrating strong correlations with the
Partial Mayo Score, IBDQ, worst pain, and patient and
clinician global ratings of disease severity (convergent
validity), and weaker correlations with measures of im-
pact on daily life (discriminant validity).
The Bowel Signs and Symptoms and the Abdominal
Symptoms scales were each able to differentiate patients
by symptom severity (p < 0.0001) based on the Partial
Mayo Score, patient global rating of disease severity, and
clinician global rating of disease severity (Fig. 1). Scale
scores for both the UC-PRO/SS scales increased (indi-
cating worse symptoms) with increasing Partial Mayo
scores (indicating higher disease severity). Similarly, UC-
PRO/SS scale scores were higher among patients who
had patient global ratings of disease severity scores ≥
Table 2 Item Descriptive Characteristics at Worst Day between Visit 1 and Visit 2 (N = 198)
Item Mean (SD) Range Floor (%) Ceiling (%) Missing (%)
Number of bowel movements 3.9 (1.60) 1–8 0 (0.0%) 6 (3.0%) 0 (0.0%)
Number of liquid bowel movements 1.8 (1.34) 0–4 48 (24.2%) 27 (13.6%) 0 (0.0%)
Blood in bowel movements 1.4 (1.48) 0–4 92 (46.5%) 23 (11.6%) 0 (0.0%)
Mucus in bowel movements 1.1 (1.36) 0–4 104 (52.5%) 14 (7.1%) 0 (0.0%)
Leak before reaching toilet 0.9 (1.21) 0–4 124 (62.6%) 6 (3.0%) 0 (0.0%)
Passing gas 2.2 (1.23) 0–4 29 (14.6%) 27 (13.6%) 0 (0.0%)
Need to have bowel movement right away 1.9 (1.35) 0–4 55 (27.8%) 20 (10.1%) 0 (0.0%)
Pain in belly 1.7 (1.25) 0–4 51 (25.8%) 14 (7.1%) 0 (0.0%)
Bloating in belly 1.5 (1.20) 0–4 60 (30.3%) 9 (4.5%) 0 (0.0%)
Abbreviations: N number, SD standard deviation
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Table 3 Correlations between UC-PRO/SS Scores and Other Clinical Variablesa,b
Clinical Variable Bowel Signs and Symptoms Rating (p value) Abdominal Symptoms Rating (p value)
Clinician Ratings:
Partial Mayo Score 0.79 (< 0.0001) 0.45 (< 0.0001)
Clinician Global Rating of Disease Severity 0.69 (< 0.0001) 0.44 (< 0.0001)
Patient Ratings:
Patient Global Rating of Disease Severity 0.67 (< 0.0001) 0.52 (< 0.0001)
IBDQ
Total score −0.70 (< 0.0001) − 0.61 (< 0.0001)
Bowel systems − 0.73 (< 0.0001) − 0.65 (< 0.0001)
Emotional health − 0.61 (< 0.0001) − 0.53 (< 0.0001)
Systemic systems − 0.51 (< 0.0001) −0.53 (< 0.0001)
Social function −0.62 (< 0.0001) −0.49 (< 0.0001)
WPAI-SHP
Absenteeism 0.35 (< 0.0001) 0.22 (0.0107)
Presenteeism 0.63 (< 0.0001) 0.45 (< 0.0001)
Work productivity loss 0.63 (< 0.0001) 0.46 (< 0.0001)
Activity impairment 0.63 (< 0.0001) 0.47 (< 0.0001)
PROMIS
Global physical health −0.21 (0.0031) − 0.28 (< 0.0001)
Global mental health −0.28 (< 0.0001) − 0.33 (< 0.0001)
General health −0.26 (0.0003) − 0.33 (< 0.0001)
Satisfaction with social role − 0.25 (0.0006) −0.28 (< 0.0001)
BPI–Worst Pain 0.57 (< 0.0001) 0.64 (< 0.0001)
Abbreviations: BM bowel movement, BPI brief pain inventory, IBDQ Inflammatory Bowel Disease Questionnaire, PROMIS Patient Reported Outcomes Measurement
Information System, UC-PRO/GI-SS Ulcerative Colitis Patient-reported Outcomes Gastrointestinal Signs and Symptoms Scale, WPAI-SHP Work Productivity and Activ-
ity Impairment–Specific Health Problems
aSpearman’s correlation coefficients
bSeven-day average scores used
Fig. 1 UC-PRO/SS Scores by Disease Activity
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median compared to those with scores below the me-
dian. Similar findings were demonstrated based on clin-
ician global rating of disease severity. Known-group
validity tables are included in the online Supplementary
Material.
Discussion
The UC-PRO/SS measure was developed to standardize
the quantification of GI signs and symptoms of UC in
clinical trials through direct patient ratings. The meth-
odology used to develop the UC-PRO/SS followed the
US FDA Guidance on PRO instrument development,
which conveys the agency’s thinking on best practices
for the development of measures and the evidence
needed for the agency’s evaluation [5]. The UC-PRO/SS
was developed based on data collection from concept
elicitation and cognitive interviews of subjects with
moderate to severe UC who were representative of the
UC target population eligible for typical clinical trials.
Measurement properties were tested in a four-week ob-
servational study of 200 adults with UC. The decision to
retain or delete items for the final measure was an itera-
tive process with consideration of floor and ceiling ef-
fects, results from the factor and Rasch analyses,
previous qualitative results, and clinical considerations.
The psychometric evaluation study included patients
with a history of very mild to moderately severe UC to
capture responses from the full range of disease activity.
The relatively large number of mild patients contributed
to the floor effects observed across items, and the results
of the Rasch analyses, which suggested little response
distinction between “none” and “mild” or between
“never” and “rarely.” Given the importance of these re-
sponse categories from a clinical perspective and to cap-
ture degrees of improvement in more severe patients,
these response options were retained, with the under-
standing that further evaluation will be needed to con-
firm their suitability and utility across populations with
severely active disease.
The final UC-PRO/SS includes two scales: Bowel Signs
and Symptoms (six items) and Abdominal Symptoms
(three items), with both scales are scored separately. Per-
formance testing of the UC-PRO/SS demonstrated evi-
dence of internal consistency and reproducibility. The
UC-PRO/SS scale scores showed moderate to high cor-
relations with other relevant measures identified a priori.
In particular, the UC-PRO/SS Bowel Signs and Symp-
toms scale score was strongly correlated with the Partial
Mayo Score (r = 0.79), IBDQ total score (r = 0.70), and
IBDQ domain of bowel systems (r = 0.73). Both UC-
PRO/SS scores also appear to have known-groups valid-
ity with significant differences in scores between disease
severity groups when defined by the Partial Mayo Score,
patient global rating of disease severity, and the clinician
global rating of disease severity.
Both scales of the UC-PRO/SS include multiple items
to better capture the bowel and abdominal symptom ex-
perience of UC from the perspective of the patient,
which allows for a more granular assessment of aspects
of the disease that are relevant and important to pa-
tients. In clinical trials of therapies for UC, the UC-
PRO/SS potentially can be used to collect data for a co-
primary endpoint or a key secondary endpoint. Therap-
ies targeting inflammation in induction studies could use
an objective marker of inflammation (e.g., endoscopy,
magnetic resonance enterography, fecal calprotectin) to
assess the co-primary or primary endpoint, with the
Bowel Signs and Symptoms module as the assessment of
a co-primary or key secondary endpoint. Therapies ex-
pected to improve functional abdominal symptoms
might use this module as the primary endpoint, while
maintenance studies of anti-inflammatory studies might
use a co-primary endpoint of an objective marker of in-
flammation and the Bowel Signs and Symptoms and Ab-
dominal Symptoms scales to demonstrate a long-term
significant impact on multiple symptom domains im-
portant to patients.
Several limitations should be noted for this research.
First, although all subjects included in the development
and evaluation of the UC-PRO/SS were required to have
clinician-confirmed UC based on biopsy, baseline endos-
copy was not required for participation in the studies.
Thus, it is unclear if subjects were experiencing active
inflammation of the colon or rectal mucosa at the time
of their participation. Second, the duration of the study
was relatively short, limiting information on the variabil-
ity in UC disease over time, and none of the participants
experienced an acute flare up of their condition, thus
limiting the data on change, including worsening and
improvement. Finally, this was an observational study
and not an interventional clinical trial, precluding re-
sponsiveness analyses, including tests of sensitivity to
change with treatment. Further research is needed to
replicate the results presented here in new samples and
to determine score sensitivity to change over time with
flares and treatment.
Conclusions
In conclusion, the UC-PRO/SS is a daily diary to gather
data on the GI signs and symptoms of UC directly from
the patient. The instrument was developed to meet regu-
latory guidelines, with initial validation evidence suggest-
ing that the UC-PRO/SS scores are reliable, valid, and
ready for use and further testing in clinical trials. The
UC-PRO/SS complements and extends information pro-
vided by the clinician, endoscopy, and biomarkers in
clinical studies.
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